Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Ph2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 Versus Each of Its Component Futuximab and Modotuximab, in Patients With Chemotherapy-Refractory Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR mAb

NCT03549338 is registered in ClinicalTrials.gov with Symphogen A/S as lead sponsor.

NCT NCT03549338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03549338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Ph2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 Versus Each of Its Component Futuximab and Modotuximab, in Patients With Chemotherapy-Refractory Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR mAb
Lead sponsor
Symphogen A/S
Phase
Phase 2
Overall status
Terminated
Start date
November 29, 2018
Completion date
March 9, 2019
Enrollment
2 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, colorectal cancer metastatic, metastatic colorectal cancer